Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Primary Myelofibrosis 4Anemia 4beta-Thalassemia 2Leukemia, Myeloid, Acute 2Thrombocytosis 1Higher-risk Myelodysplastic Syndrome 1Hematologic Neoplasms 1Granulosa cell tumor of the ovary 1

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22venetoclax 20Thiotepa 20Sirolimus 20Azacitidine 20Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × luspatercept × Clear all
NCT07539779 2026-04-20

Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis

Nanfang Hospital, Southern Medical University

Phase 2/3 Not yet recruiting
196 enrolled
MyeloidOther hematologic neoplasm

Hematologic Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡